Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Philogen SpA ( (IT:PHIL) ) is now available.
Philogen S.p.A. has made available the minutes of its Shareholders’ Meeting held on April 29, 2025. This announcement underscores the company’s commitment to transparency and governance, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the biotechnology sector.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company focused on the research and development of pharmaceutical products, particularly targeted anti-cancer drugs. Utilizing technologies like Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries, Philogen develops ligands that deliver therapeutic agents specifically to tumor masses, minimizing damage to healthy tissues. The company aims to create innovative treatments for diseases lacking effective therapies, primarily in oncology but also potentially in chronic inflammatory diseases.
YTD Price Performance: 14.87%
Average Trading Volume: 9,439
Technical Sentiment Signal: Buy
Current Market Cap: €655M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.